Previous close | 0.0600 |
Open | 0.0620 |
Bid | 0.0650 x N/A |
Ask | 0.0800 x N/A |
Day's range | 0.0600 - 0.0620 |
52-week range | 0.0600 - 0.0620 |
Volume | |
Avg. volume | N/A |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
New lipid biomarkers central to development of breast cancer diagnostic blood test are coveredPatent application will underpin future global filings securing key features of BCAL’s test SYDNEY, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Breast cancer screening and diagnostic company BCAL Diagnostics Limited (ASX:BDX, ‘BCAL’ or the ‘Company’) is pleased to announce the filing of a provisional patent application number 2022901245 at IP Australia covering key lipid biomarkers that form part of its
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...